Modified hexa-acylated neisserial LPS
Inventors
ZARIRI, Afshin • Pupo Escalona, Elder • Van Der Ley, Peter André
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
The present invention relates to neisserial LPS having a hexa-acylated lipid A moiety, wherein the hexa-acylated lipid A moiety is modified as compared to the lipid A moiety of a wild-type neisserial LPS in that it comprises a palmitoleoyl instead of a lauroyl secondary acyl chain on the glucosamine at the non-reducing end of the lipid A moiety. The invention further relates to mixtures of the hexa-acylated LPS with the corresponding penta-acylated LPS, lacking a secondary acyl chain on the glucosamine at the non-reducing end of the lipid A moiety. The invention also relates to neisserial bacteria that have been genetically modified to reduce expression of the endogenous lpxL1 gene and to introduce expression of a heterologous thermosensitive lpxP gene for producing the hexa- and penta-acylated LPS. By selecting the time and/or temperature at which the bacterium is grown, it is feasible to increase or decrease the amount of hexa-acylated lipid A structure relative to the corresponding penta-acylated structure and thereby modulate the TLR4 agonist activity of the neisserial LPS of the invention, to the exact level of activity required for a particular immunotherapeutic approach.
Core Innovation
The invention provides a composition comprising a mixture of neisserial LPS having a hexa-acylated lipid A moiety and a neisserial LPS having a penta-acylated lipid A moiety. In the hexa-acylated lipid A moiety, a secondary acyl chain bound to the primary acyl chain on the glucosamine at the non-reducing end is modified to be palmitoleoyl instead of lauroyl. In the penta-acylated lipid A moiety, the lipid A moiety is modified as compared to a wild-type neisserial LPS in that it lacks that secondary acyl chain bound to the primary acyl chain on the glucosamine at the non-reducing end.
The document describes producing controlled hexa:penta mixtures in genetically modified Neisseria by reducing endogenous lpxL1 lauroyl acyltransferase activity and by heterologously expressing an lpxP palmitoleoyltransferase that is thermosensitive or cold-shock-induced. It further describes that the relative hexa versus penta fractions can be modulated by culturing temperature and time, and that this modulation is linked to TLR4 agonist activity and cytokine profiles.
The document also characterizes purified LOS/LPS by mass spectrometry, including intact ion peak characterization and fragmentation assignments with proposed LOS compositions for multiple Neisseria mutants. It additionally describes immunostimulatory data in human MM6 cells after stimulation with purified LPS mutants, measuring cytokines including IL-6, IP-10, IL-1β, and MCP-1.
Claims Coverage
The independent claim coverage centers on a mixture of two neisserial LPS species that differ in lipid A acylation state and in the identity or absence of the secondary acyl chain on the non-reducing-end glucosamine.
Hexa-acylated neisserial LPS with palmitoleoyl secondary acyl chain
A neisserial LPS having a hexa-acylated lipid A moiety modified as compared to the lipid A moiety of a wild-type neisserial LPS in that it has a palmitoleoyl instead of a lauroyl secondary acyl chain bound to the primary acyl chain on the glucosamine at the non-reducing end of the lipid A moiety.
Penta-acylated neisserial LPS lacking the secondary acyl chain
A neisserial LPS with a penta-acylated lipid A moiety modified as compared to the lipid A moiety of a wild-type neisserial LPS in that it lacks the secondary acyl chain bound to the primary acyl chain on the glucosamine at the non-reducing end of the lipid A moiety.
The claim coverage centers on a composition combining a hexa-acylated neisserial LPS with a palmitoleoyl secondary acyl chain and a penta-acylated neisserial LPS lacking that secondary acyl chain, relative to wild-type neisserial LPS lipid A at the non-reducing-end glucosamine.
Stated Advantages
Provides a defined TLR4 agonist activity by modulating hexa versus penta fractions in modified neisserial LPS.
Induces cytokine profiles in vitro, including IL-6, IL-1β, IP-10, and MCP-1, via TLR4 stimulation.
Documented Applications
Immunotherapy medicament use as a TLR4 agonist, including pharmaceutical vaccine compositions in acellular and whole-cell formats and compositions formulated as outer membrane vesicles (OMVs).
Immunostimulatory assessment in human MM6 cells using purified LPS mutants, measuring cytokine release (IL-6, IP-10, IL-1β, MCP-1) across serial LPS dilutions and expressing percent responses relative to a reference LPS at 5 ng/mL.
Interested in licensing this patent?